{"version":"1.0","type":"rich","provider_name":"Kabul Press","provider_url":"https:\/\/www.kabulpress.org","title":"Analysis: HIV generics under threat from tighter patenting rules","author_name":"","width":"600","height":"400","url":"https:\/\/mail.bamyanpress.com\/article32123.html","html":"\u003Ch4 class='title'\u003E\u003Ca href='https:\/\/mail.bamyanpress.com\/article32123.html'\u003EAnalysis: HIV generics under threat from tighter patenting rules\u003C\/a\u003E\u003C\/h4\u003E\u003Cblockquote class='spip'\u003E\n\u003Cp\u003EVIENNA Monday, August 02, 2010 (IRIN) - Most of the estimated 5.2 million people worldwide on antiretroviral (ARV) treatment are taking generic versions manufactured primarily in India, but tighter global intellectual property rights and trade rules could shut down \"the pharmacy of the developing world\".\u003C\/p\u003E\n\u003C\/blockquote\u003E\n"}